Estimates Revisions Newron Pharmaceuticals S.p.A. Deutsche Boerse AG
Stocks
NP5
IT0004147952
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.80 EUR | +7.81% |
|
+3.49% | -49.91% |
| 05-05 | Edison Is Not Overly Concerned About a Trial Suspension |  |
| 04-30 | US FDA Halts New Patient Enrollment at Newron's Phase 3 Trial for Schizophrenia Treatment | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- NWRN Stock
- NP5 Stock
- Consensus Newron Pharmaceuticals S.p.A.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
